Dimethyl fumarate (Skilarence®)

Assessment Status Rapid Review Complete
Drug Dimethyl fumarate
Brand Skilarence®
Indication For the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.
Assessment Process
Rapid review commissioned 15/01/2018
Rapid review completed 06/02/2018
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

The HSE has approved reimbursement following a price negotiation February 2019.